// October 14, 2025
Concentrated origins, widespread risk: New USP insights on key starting materials...
Understanding where pharmaceutical KSMs are made can help address vulnerabilities in the medicine supply chain.
// November 06, 2025
Working Collaboratively for a Quality and Resilient Supply Chain: Conversation with A...
Generic medicines account for over 90% of prescriptions filled in the U.S., providing critical savings throughout the healthcare system, while continuing to improve access and affordability for patients at the point of care.
// October 14, 2025
Concentrated origins, widespread risk: New USP insights on key starting materials...
Understanding where pharmaceutical KSMs are made can help address vulnerabilities in the medicine supply chain.
// September 09, 2025
Nitrosamines: An urgent demand for vigilance and reliable testing...
Nitrosamines are well known to regulators and industry as probable human carcinogens. But this time, the threat isn’t from synthesis or degradation—it’s leachables.
// October 30, 2025
Tackling Extractable and Leachable Risks Through Forward-Thinking Collaboration...
Explore insights from GRXBiosims on pharma quality threats, extractables and leachables, and USP’s evolving standards to protect patient safety.
Featured Videos
// May 24, 2018
Quality Medicines for Malaria
Marie Lamy with Asia Pacific Leaders Malaria Alliance discusses how one country is tackling drug resistance in order to eradicate Malaria.
// May 24, 2018
Poor quality medicines and drug resistance
Harvard professor and physician Ashish Jha describes how poor quality medicines create the perfect opportunity for superbugs.
// May 24, 2018
Quality medicines and sub-Saharan Africa
Global health advocate Mirfin Moundu talks about the dangers of poor quality medicines and how they are a threat to many Africans in treating infectious diseases and non-communicable diseases.
QMBlog Content
Discover More:
// October 03, 2025
USP Announces the Council of the Convention Membership for 2025-2030 ...
USP announces 2025–2030 Council of the Convention, representing over 450 global organizations guiding medicine, supplement, and food quality standards.
// July 28, 2025
India and the EU dominate API manufacturing for the most-used ATC-3 therapeutic class...
This blog continues our exploration of global pharmaceutical supply chain vulnerabilities, specifically the geographic concentration of active pharmaceutical ingredient (API) manufacturing.
// May 23, 2025
A path to locally manufactured quality medicines: Building capacity in Africa to cond...
Bioequivalence (BE) studies are essential to assuring quality generic medicines. Yet Africa faces several challenges in conducting BE studies and increasing the demand for and availability of quality generics. Read the blog.
// April 22, 2025
USP Resolutions: Reflections and the Cycle Ahead
Explore Anthony Lakavage's reflections on USP's 2020-2025 cycle and the new Resolutions that will help guide USP into the future. Discover how collective expertise and innovative strategies are shaping medicine quality and improving people's health.